R&D Spending Showdown: Viatris Inc. vs Intra-Cellular Therapies, Inc.

Viatris vs Intra-Cellular: A Decade of R&D Investment

__timestampIntra-Cellular Therapies, Inc.Viatris Inc.
Wednesday, January 1, 201421226345581800000
Thursday, January 1, 201587718074671900000
Friday, January 1, 201693831530876700000
Sunday, January 1, 201779419009857900000
Monday, January 1, 2018132166913822200000
Tuesday, January 1, 201989124838778200000
Wednesday, January 1, 202065782137512600000
Friday, January 1, 202188845513681000000
Saturday, January 1, 2022134715000662200000
Sunday, January 1, 2023180142000910700000
Loading chart...

Data in motion

The R&D Race: Viatris Inc. vs Intra-Cellular Therapies, Inc.

In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Viatris Inc. and Intra-Cellular Therapies, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Viatris Inc. consistently outspent Intra-Cellular Therapies, with its R&D expenses peaking at approximately 910 million in 2023, a 56% increase from its 2014 spending. In contrast, Intra-Cellular Therapies, Inc. showed a more dynamic growth trajectory, with its R&D spending surging by over 740% during the same period, reaching around 180 million in 2023. This divergence highlights Viatris's steady commitment to innovation, while Intra-Cellular Therapies, Inc. has rapidly scaled its efforts, potentially signaling a strategic pivot towards aggressive growth and development. As these companies continue to invest in R&D, their future breakthroughs could reshape the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025